Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes t...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | Brasil |
| Institución: | Associação Brasileira de Transplante de Órgãos (ABTO) |
| Repositorio: | Brazilian Journal of Transplantation |
| Idioma: | inglés portugués |
| OAI Identifier: | oai:ojs3.emnuvens.com.br:article/563 |
| Acceso en línea: | https://bjt.emnuvens.com.br/revista/article/view/563 |
| Access Level: | acceso abierto |
| Palabra clave: | Glucagon-like Peptide-1 Receptor Agonists Kidney Transplant Diabetes Mellitus Agonistas do Receptor de Peptídeo Semelhante ao Glucagon-1 Transplante Renal |
| Sumario: | Objetives: The incidence of posttransplant diabetes and the elevated cardiovascular (CV) risk among transplant recipients are on the rise. Glucagon-like peptide agonists have the potential to mitigate the effects of immunosuppressive drugs, addressing both hyperglycemia and weight gain. This makes them appealing for use in this population, given their CV and renoprotective benefits. Nevertheless, there is insufficient substantial evidence regarding their efficacy in diabetic kidney transplant recipients (KTR). Methods: The objective of this retrospective study was to assess the effectiveness and safety of glucagon-like peptide agonists in KTR. The primary focus was to evaluate their impact on various parameters, such as hemoglobin A1c levels, body mass index (BMI), lipid panel, hemoglobin levels, renal allograft function (estimated glomerular filtration rate [eGFR]), and urinary protein-to-creatinine ratio. Results: During a median observation period of 18 months, this investigation included 64 renal transplant patients. Median eGFR at baseline was 61.9 mL/min/1.73 m2 and remained stable throughout the follow-up. Median HbA1c decreased from 7.5 to 7% (95%CI; p < 0.002). A significant improvement in BMI and lipid panel were also observed. We did not observed significant changes regarding median creatinine and urinary protein:creatinine ratio levels. No side effects justified discontinuation of the drug. Conclusion: This study shows that the use of glucagon-like peptide agonists is feasible and well-tolerated in KTR, with no significant side effects observed. Subsequent studies are needed to explore whether glucagonlike peptide agonists can effectively improve allograft survival in these patients. |
|---|